Replies to post #606 on Biotech Ideas

[gfp927z]

>> MEIP <<

Looks like they decided to not pursue that Phase 3 program, after further talks with the FDA, though their partner will continue it in Japan. And the $41 mil in 'net income' turns out to be from "recognition of deferred revenue associated primarily with the termination of the Kyowa Kirin Commercialization Agreement in July 2023" (link below), so not real net income derived from actual product sales. The cash level is $81 mil, but looks like the burn rate is just under $20 mil per quarter, so they project having sufficient cash for approx 1 year. Clinical programs look like Phase 1 and 1b, so early stage. So I guess MEIP's low $39 mil market cap is appropriate, all things considered -


https://finance.yahoo.com/news/mei-pharma-reports-first-quarter-210500033.html



---

[bladerunner1717]

Hey gfp,

I don't follow MEIP any longer and haven't for a long time.

My largest position in terms of dollars is IOVA. Lififeucel recently approved and he stock has risen considerable.

In terms of shares, CRDF is my largest position. I was upgraded at Piper Sandler last week with the price target being raised from $5 to $7.

Other large positions of mine include IMMP, BCAB, JSPR, and GRTS.

Bladerunner